BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Elfetabart drozuntecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Elfetabart drozuntecan\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05914116-2414@assetmemo.bio
DTSTAMP:20261121T005948Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Elfetabart drozuntecan: Phase 1/2 readout est. (NCT05914116)
DESCRIPTION:Elfetabart drozuntecan\, phase 1/2.\nStudy: A Phase 1/2a Study 
 of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors\nEstimated primary c
 ompletion: December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/elfetabart-drozuntecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05914116
URL:https://assetmemo.bio/drug/elfetabart-drozuntecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892548-2414@assetmemo.bio
DTSTAMP:20261121T005948Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Elfetabart drozuntecan: Phase 1/2 readout est. (NCT06892548)
DESCRIPTION:Elfetabart drozuntecan\, phase 1/2.\nStudy: A Clinical Study to
  Investigate the Efficacy and Safety of an Investigational Combination The
 rapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer\nEstimat
 ed primary completion: September 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/elfetabart-drozuntecan#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06892548
URL:https://assetmemo.bio/drug/elfetabart-drozuntecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953089-2414@assetmemo.bio
DTSTAMP:20261121T005948Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Elfetabart drozuntecan: Phase 2 readout est. (NCT06953089)
DESCRIPTION:Elfetabart drozuntecan\, phase 2.\nStudy: DB-1311 in Combinatio
 n With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors\nEstimated pr
 imary completion: 30 June 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/elfetabart-drozuntecan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06953089
URL:https://assetmemo.bio/drug/elfetabart-drozuntecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365995-2414@assetmemo.bio
DTSTAMP:20261121T005948Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Elfetabart drozuntecan: Phase 3 readout est. (NCT07365995)
DESCRIPTION:Elfetabart drozuntecan\, phase 3\, Metastatic Castration-Resist
 ant Prostate Cancer.\nStudy: A Phase III Trial of BNT324 Versus Docetaxel 
 in Metastatic Castration-resistant Prostate Cancer\nEstimated primary comp
 letion: February 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/elfetabart-drozuntecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07365995
URL:https://assetmemo.bio/drug/elfetabart-drozuntecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
